InMed Pharmaceuticals (INM) just unveiled an announcement.
InMed Pharmaceuticals Inc. has been given an additional 180 days, until September 16, 2024, by Nasdaq to meet the minimum bid price requirement and avoid delisting. The company’s shares currently do not meet the $1.00 minimum bid price, but if the shares reach this threshold for 10 consecutive days before the deadline, they will regain compliance. The company is considering all available options, including a potential reverse stock split, to resolve the issue. The extension does not immediately affect the trading of InMed’s shares, which continue to be listed on the Nasdaq Capital Market.
Learn more about INM stock on TipRanks’ Stock Analysis page.
